RayKnowChina Research Map
Shortlist

RecruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06634979, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;

    Inclusion criterion 5

  3. Patients with clinical stage T1N0M0 surgically resectable;

    Inclusion criterion 8

    T1N0M0 with a clinical stage other than 0.5 < CTR < 1 and a diameter of ≤ 2 cm;

    Exclusion criterion 1

  4. ECOG score 0 or 1;

    Inclusion criterion 3

  5. cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06634979, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Volunteer to participate in a clinical study and be willing to follow and have the ability to complete all trial procedures;
  • Age 18-80 years at time of signing informed consent (including threshold);
  • ECOG score 0 or 1;
  • No previous surgery for lung cancer;
  • Intraoperative or postoperative pathologically confirmed non-small cell lung cancer;
  • Single pulmonary nodule with mixed ground glass on CT, or multiple pulmonary nodules but the main lesion is the above nodules;
  • The proportion of solid components of the nodule is between 0.5 and 1, and the total size of the nodule is less than or equal to 2 cm;
  • Patients with clinical stage T1N0M0 surgically resectable;
  • Primary treatment without radiotherapy or chemotherapy.

Exclusion Criteria:

  • T1N0M0 with a clinical stage other than 0.5 < CTR < 1 and a diameter of ≤ 2 cm;
  • Inability to perform complete surgical resection;
  • cytology or histopathology confirms that it is a lung malignant tumor other than non-small cell lung cancer;
  • Previous surgery for lung cancer;
  • Patients who have received radiotherapy or chemotherapy for non-primary treatment.

Quoted from ClinicalTrials.gov, NCT06634979, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06634979, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06634979